BR112022026397A2 - Métodos para tratar câncer usando derivados de amida de heteroaril-bifenila - Google Patents

Métodos para tratar câncer usando derivados de amida de heteroaril-bifenila

Info

Publication number
BR112022026397A2
BR112022026397A2 BR112022026397A BR112022026397A BR112022026397A2 BR 112022026397 A2 BR112022026397 A2 BR 112022026397A2 BR 112022026397 A BR112022026397 A BR 112022026397A BR 112022026397 A BR112022026397 A BR 112022026397A BR 112022026397 A2 BR112022026397 A2 BR 112022026397A2
Authority
BR
Brazil
Prior art keywords
methods
heteroaryl
amide derivatives
cancer
treatting
Prior art date
Application number
BR112022026397A
Other languages
English (en)
Inventor
Li Shijie
Vilalta-Colomer Marta
Zeng Yibin
Zhang Penglie
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of BR112022026397A2 publication Critical patent/BR112022026397A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

MÉTODOS PARA TRATAR CÂNCER USANDO DERIVADOS DE AMIDA DE HETEROARIL-BIFENILA. São fornecidos no presente documento métodos de tratamento de certos cânceres que compreendem administrar ao sujeito que precisa dos mesmos uma quantidade eficaz de um composto da Fórmula (I) incluindo estereoisômeros e sais farmaceuticamente aceitáveis dos mesmos, em que R1, R2, R3, R4, Ra e Rb são conforme definidos no presente documento.
BR112022026397A 2020-06-23 2021-06-22 Métodos para tratar câncer usando derivados de amida de heteroaril-bifenila BR112022026397A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063042807P 2020-06-23 2020-06-23
PCT/US2021/038339 WO2021262627A1 (en) 2020-06-23 2021-06-22 Methods of treating cancer using heteroaryl-biphenyl amide derivatives

Publications (1)

Publication Number Publication Date
BR112022026397A2 true BR112022026397A2 (pt) 2023-03-14

Family

ID=79022859

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022026397A BR112022026397A2 (pt) 2020-06-23 2021-06-22 Métodos para tratar câncer usando derivados de amida de heteroaril-bifenila

Country Status (14)

Country Link
US (2) US20210393759A1 (pt)
EP (1) EP4167991A1 (pt)
JP (1) JP2023531970A (pt)
KR (1) KR20230040993A (pt)
CN (1) CN116472045A (pt)
AU (1) AU2021297216A1 (pt)
BR (1) BR112022026397A2 (pt)
CA (1) CA3187605A1 (pt)
CL (1) CL2022003716A1 (pt)
CO (1) CO2023000703A2 (pt)
IL (1) IL299206A (pt)
MX (1) MX2022016554A (pt)
TW (1) TW202216694A (pt)
WO (1) WO2021262627A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111225665B (zh) 2017-08-08 2023-12-08 凯莫森特里克斯股份有限公司 大环免疫调节剂
WO2019165043A2 (en) 2018-02-22 2019-08-29 Chemocentryx, Inc. Indane-amines as pd-l1 antagonists
US11872217B2 (en) 2019-07-10 2024-01-16 Chemocentryx, Inc. Indanes as PD-L1 inhibitors
KR20220084119A (ko) * 2019-10-16 2022-06-21 케모센트릭스, 인크. Pd-l1 질환의 치료를 위한 헤테로아릴-바이페닐 아미드
JP2022551972A (ja) 2019-10-16 2022-12-14 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１疾患の治療のためのヘテロアリール－ビフェニルアミン

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201402004YA (en) * 2011-11-14 2014-05-29 Cephalon Inc Uracil derivatives as axl and c-met kinase inhibitors
WO2013085802A1 (en) * 2011-12-06 2013-06-13 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
CN106674136B (zh) * 2016-12-23 2019-07-02 中国医科大学 嘧啶类抗肿瘤化合物及其制备方法
WO2020232256A1 (en) * 2019-05-15 2020-11-19 Chemocentryx, Inc. Triaryl compounds for treatment of pd-l1 diseases
KR20220084119A (ko) * 2019-10-16 2022-06-21 케모센트릭스, 인크. Pd-l1 질환의 치료를 위한 헤테로아릴-바이페닐 아미드

Also Published As

Publication number Publication date
CO2023000703A2 (es) 2023-01-26
CL2022003716A1 (es) 2023-06-30
IL299206A (en) 2023-02-01
EP4167991A1 (en) 2023-04-26
WO2021262627A1 (en) 2021-12-30
TW202216694A (zh) 2022-05-01
JP2023531970A (ja) 2023-07-26
MX2022016554A (es) 2023-04-10
AU2021297216A1 (en) 2023-02-02
US20210393759A1 (en) 2021-12-23
US20240115682A1 (en) 2024-04-11
CN116472045A (zh) 2023-07-21
CA3187605A1 (en) 2021-12-30
KR20230040993A (ko) 2023-03-23

Similar Documents

Publication Publication Date Title
BR112022026397A2 (pt) Métodos para tratar câncer usando derivados de amida de heteroaril-bifenila
CL2021001508A1 (es) Derivados de 2-oxoquinazolina como inhibidores de metionina adenosiltransferasa 2a
ZA202307575B (en) Methods and modified nucleosides for treating coronavirus infections
BR112023019797A2 (pt) Inibidor derivado heterocíclico e método de preparação do mesmo e aplicação do mesmo
BR112013026345A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
ECSP21080535A (es) Compuestos y métodos para el tratamiento de covid-19
BR112022003490A2 (pt) Método de tratamento do câncer de mama e mama metastático, método para degradação seletiva, método para inibir uma quinase, kit, composição líquida, e, método de produção de uma composição líquida
MX2022009044A (es) Conjugado de farmaco de derivado de eribulin, metodo de preparacion y aplicacion del mismo en medicina.
BR112022021962A2 (pt) Imidazopiridazinas como moduladores de il-17
BR112021020285A2 (pt) Métodos e composições para degradação de proteína alvejada
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
BR112022000713A2 (pt) Imidazopirimidinas como inibidores de eed e o uso das mesmas
BR112021006229A2 (pt) composto, composição farmacêutica, e, método para tratamento de um câncer
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
EA202192433A1 (ru) Соединения, полезные в терапии вич
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
BR112021019817A2 (pt) Compostos de pirrol
EA202090959A1 (ru) Аминзамещенные гетероциклические соединения в качестве ингибиторов ehmt2, их соли и способы их синтеза
BR112022022988A2 (pt) Métodos de tratamento do câncer de próstata
BR112021018335A2 (pt) Derivados de benzodiazepina como inibidores de rsv
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica
BR112022017779A2 (pt) Imunomodulação de azaletos de o-het-arila